Gene Therapy

  • |

    We Fund the Science. They Set the $3.95 Million Price.

    ByPhil McCracken

    I followed the Kebilidi invoice and found NIH’s NCATS on the public-science side, PTC Therapeutics at the commercial finish line, and a stated price of $3.95 million waiting like it had its own congressional parking space. That does not mean public research invented every molecule or erased the company’s costs. It does mean taxpayers and patients deserve a seat at the pricing table when public support helped move a rare-disease therapy from scientific risk toward treatment.

    One-time gene therapies are complex and expensive; nobody is asking the lab to accept payment in inspirational refrigerator magnets. But complexity cannot be the magic word that makes public investment disappear from the conversation. The public helped build the runway, while private billing arrived dressed as the sole owner of aviation. Follow the invoice: government may not have created every part of Kebilidi, but families should not be treated like silent partners who receive only the receipt. Fair pricing and fair taxes are the minimum decent terms.

  • |

    Skysona and the $3 Million Toll Booth

    ByPhil McCracken

    I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

    The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.

End of content

End of content